Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a second PER.C6® commercial license agreement with Ferring Pharmaceuticals. This license agreement allows Ferring to use the PER.C6® cell line in the production of a specific therapeutic protein. As with the first license, announced in May of 2005, the protein will be applied in the field of women's health care. Financial details were not disclosed.
